Mineralys Therapeutics Inc
MLYS13.385USD
-0.280-2.05%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
868.37MCap. mercado
PérdidaP/E TTM
Más Datos de Mineralys Therapeutics Inc Compañía
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Información de la empresa
Símbolo de cotizaciónMLYS
Nombre de la empresaMineralys Therapeutics Inc
Fecha de salida a bolsaFeb 10, 2023
Director ejecutivoMr. Jon Congleton
Número de empleados51
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 10
Dirección150 N. Radnor Chester Road
CiudadRADNOR
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19087
Teléfono18883786240
Sitio Webhttps://mineralystx.com/
Símbolo de cotizaciónMLYS
Fecha de salida a bolsaFeb 10, 2023
Director ejecutivoMr. Jon Congleton
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 19 de jul
Actualizado: sáb., 19 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
Accionistas
Accionistas
Proporción
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
38.81%
Hedge Fund
23.09%
Venture Capital
22.96%
Investment Advisor/Hedge Fund
16.44%
Individual Investor
1.40%
Research Firm
1.10%
Pension Fund
0.67%
Private Equity
0.61%
Bank and Trust
0.09%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
285
69.20M
106.19%
+10.20M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
TCG Crossover Management, LLC
2.47M
3.79%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Caligan Partners, LP
2.15M
3.3%
+1.14M
+112.60%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.82%
SPDR S&P Biotech ETF
Proporción0.2%
iShares Micro-Cap ETF
Proporción0.12%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.1%
iShares Biotechnology ETF
Proporción0.06%
iShares Russell 2000 Growth ETF
Proporción0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.03%
ProShares UltraPro Russell2000
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
